Increasing focus on LCM throughout a product’s lifecycle will help companies maximize product sales now and better prepare a counter-generics strategy in the future. This study includes data from 100+ pharmaceutical lifecycle management strategies from life science companies of all sizes and across multiple geographic locations.
Create robust counter-generics strategies to retain products’ market share and prevent revenue erosion after patent expiration.
Reinforce new product planning teams to create a strong commercial voice for developing brands and support business development.
Master portfolio management and drive coordinated execution using benchmarks and best practices from pre-clinical development through late lifecycle management.
Empower business development teams and licensing groups to pursue partnership opportunities and close the right deals. Benchmark pharma and biotech BD&L resources and improve deal-making protocols and alliance management.
Realize deal value, target the right opportunities and complete post-M&A integration as quickly as possible.
Craft a robust alliance management strategy to bridge organizational gaps and drive pharma partnership project success while preparing for contingencies.
Uncover the strategy, science, investments and timing behind common relaunch strategies.